Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- Registration Number
- NCT04784000
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Brief Summary
This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
- Females must have a negative pregnancy test at Screening and prior to dosing
- Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
- Willing to comply with the study requirements and to provide written informed consent
Exclusion Criteria
- Pregnant or breastfeeding
- Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19
- Abuse of alcohol or drugs
- Use of other investigational drugs within 28 days of dosing
- Use of other prescription drugs with 28 days of dosing
- Other clinically significant medical conditions or laboratory abnormalities
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Pharmacokinetics (PK) of AT-527 (RO7496998) Day 1 vs Day 26 Area under the concentration-time curve (AUC)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of P-glycoprotein induction by carbamazepine in NCT04784000?
How does carbamazepine affect the CYP3A4 metabolism of AT-527 in phase 1 trials?
Are there biomarkers associated with AT-527 pharmacokinetic interactions in healthy volunteers?
What adverse events are reported in Atea Pharmaceuticals' AT-527 drug interaction studies?
How does AT-527 compare to other antiviral agents in P-glycoprotein inhibitor trials?
Trial Locations
- Locations (1)
Atea Study Site
🇨🇦Montreal, Quebec, Canada
Atea Study Site🇨🇦Montreal, Quebec, Canada